Literature DB >> 34673944

C/D box snoRNA SNORD113-6/AF357425 plays a dual role in integrin signalling and arterial fibroblast function via pre-mRNA processing and 2'O-ribose methylation.

Eva van Ingen1,2, Daphne A L van den Homberg1,2, M Leontien van der Bent1,2, Hailiang Mei3, Nikolina Papac-Milicevic4, Veerle Kremer5, Reinier A Boon5,6,7, Paul H A Quax1,2, Johann Wojta8,9, A Yaël Nossent1,2,4,8.   

Abstract

We have previously shown that C/D box small nucleolar RNAs (snoRNAs) transcribed from the DLK1-DIO3 locus on human chromosome 14 (14q32) are associated with cardiovascular disease. DLK1-DIO3 snoRNAs are 'orphan snoRNAs' that have no known targets. We aimed to identify RNA targets and elucidate the mechanism-of-action of human SNORD113-6 (AF357425 in mice). As AF357425-knockout cells were non-viable, we induced overexpression or inhibition of AF357425 in primary murine fibroblasts and performed RNA-Seq. We identified several pre-mRNAs with conserved AF357425/SNORD113-6 D'-seed binding sites in the last exon/3' untranslated region (3'UTR), which directed pre-mRNA processing and splice-variant-specific protein expression. We also pulled down the snoRNA-associated methyltransferase fibrillarin from AF357425-High versus AF357425-Low fibroblast lysates, followed by RNA isolation, ribosomal RNA depletion and RNA-Seq. Identifying mostly mRNAs, we subjected these to PANTHER pathway analysis and observed enrichment for genes in the integrin pathway. We confirmed 2'O-ribose methylation in six integrin pathway mRNAs (MAP2K1, ITGB3, ITGA7, PARVB, NTN4 and FLNB). Methylation and mRNA expressions were decreased while mRNA degradation was increased under AF357425/SNORD113-6 inhibition in both murine and human primary fibroblasts, but effects on protein expression were more ambiguous. Integrin signalling is crucial for cell-cell and cell-matrix interactions, and correspondingly, we observed altered human primary arterial fibroblast function upon SNORD113-6 inhibition.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34673944      PMCID: PMC8976432          DOI: 10.1093/hmg/ddab304

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  45 in total

Review 1.  Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs.

Authors:  T Kiss
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

2.  Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosis.

Authors:  Sabine M J Welten; Rob C M de Jong; Anouk Wezel; Margreet R de Vries; Martin C Boonstra; Laura Parma; J Wouter Jukema; Tetje C van der Sluis; Ramon Arens; Ilze Bot; Sudhir Agrawal; Paul H A Quax; A Yaël Nossent
Journal:  Atherosclerosis       Date:  2017-04-13       Impact factor: 5.162

3.  Identification of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization.

Authors:  J Cavaillé; K Buiting; M Kiefmann; M Lalande; C I Brannan; B Horsthemke; J P Bachellerie; J Brosius; A Hüttenhofer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

Review 4.  Regulation of alternative splicing by snoRNAs.

Authors:  S Kishore; S Stamm
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2006

5.  The 14q32 microRNA-487b targets the antiapoptotic insulin receptor substrate 1 in hypertension-induced remodeling of the aorta.

Authors:  A Yaël Nossent; Tilde V Eskildsen; Lene B Andersen; Peter Bie; Hasse Brønnum; Mikael Schneider; Ditte C Andersen; Sabine M J Welten; Pia L Jeppesen; Jaap F Hamming; Jakob L Hansen; Paul H Quax; Søren P Sheikh
Journal:  Ann Surg       Date:  2013-11       Impact factor: 12.969

6.  Inhibition of 14q32 MicroRNAs miR-329, miR-487b, miR-494, and miR-495 increases neovascularization and blood flow recovery after ischemia.

Authors:  Sabine M J Welten; Antonius J N M Bastiaansen; Rob C M de Jong; Margreet R de Vries; Erna A B Peters; Martin C Boonstra; Søren P Sheikh; Nicola La Monica; Ekambar R Kandimalla; Paul H A Quax; A Yaël Nossent
Journal:  Circ Res       Date:  2014-08-01       Impact factor: 17.367

Review 7.  MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles.

Authors:  Eva van Rooij; Eric N Olson
Journal:  Nat Rev Drug Discov       Date:  2012-10-19       Impact factor: 84.694

8.  Human box C/D snoRNAs with miRNA like functions: expanding the range of regulatory RNAs.

Authors:  Markus Brameier; Astrid Herwig; Richard Reinhardt; Lutz Walter; Jens Gruber
Journal:  Nucleic Acids Res       Date:  2010-09-15       Impact factor: 16.971

9.  Modification of messenger RNA by 2'-O-methylation regulates gene expression in vivo.

Authors:  Brittany A Elliott; Hsiang-Ting Ho; Srivathsan V Ranganathan; Sweta Vangaveti; Olga Ilkayeva; Hala Abou Assi; Alex K Choi; Paul F Agris; Christopher L Holley
Journal:  Nat Commun       Date:  2019-07-30       Impact factor: 14.919

Review 10.  An Emerging Role for isomiRs and the microRNA Epitranscriptome in Neovascularization.

Authors:  Reginald V C T van der Kwast; Paul H A Quax; A Yaël Nossent
Journal:  Cells       Date:  2019-12-25       Impact factor: 6.600

View more
  2 in total

Review 1.  Change of Heart: the Epitranscriptome of Small Non-coding RNAs in Heart Failure.

Authors:  Tamar Woudenberg; Nyika D Kruyt; Paul H A Quax; A Yaël Nossent
Journal:  Curr Heart Fail Rep       Date:  2022-07-25

2.  C/D box snoRNA SNORD113-6 guides 2'-O-methylation and protects against site-specific fragmentation of tRNALeu(TAA) in vascular remodeling.

Authors:  Eva van Ingen; Pleun A M Engbers; Tamar Woudenberg; M Leontien van der Bent; Hailiang Mei; Johann Wojta; Paul H A Quax; A Yaël Nossent
Journal:  Mol Ther Nucleic Acids       Date:  2022-09-17       Impact factor: 10.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.